Precision for prostate cancer
Thursday 10 April 2025 | 18:30 – 20:00 BST
th
†
Pluvicto is indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy or who are not medically suitable for taxanes.
®
1
†
Image used on this website is for representative purposes only and is not a real patient.
Pluvicto 1,000 MBq/mL solution for injection/infusion. Summary of Product Characteristics.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report
or alternatively email medinfo.uk@novartis.com or call 01276 698370
This webinar is organised and funded by Novartis Pharmaceuticals UK Ltd and is classed as promotional under the Association of the British Pharmaceutical Industry (ABPI) Code. It is intended for UK healthcare professionals only.
Company products will be discussed at this webinar and United Kingdom prescribing information is available by clicking on the blue button above.
This website is created and funded by Novartis Pharmaceuticals UK Ltd.
UK | March 2025 | FA-11354943
Your attendance at the event is governed by our Healthcare Professional Event Attendance Terms. By attending the event, you are agreeing to be bound by such terms.
The chat tool to the right is managed by Square Production Ltd on behalf of Novartis.
1
®